Hansa Medical to present IdeS at the 2014 BIO International Convention in San Diego, USA, on June 26
The 2014 BIO International Convention (Biotechnology Industry Organization), June 23 through 26, will be held at the San Diego Convention Center in San Diego, California. The convention gathers international and US-based industry leading parties, prominent keynote speakers, and attracts extensive media coverage.
For more information about the event, please visit: www.convention.bio.org
The CEO presentation will emphasize IdeS’ promising deactivating effect on IgG-antibodies, recently established in a clinical Phase I study and IdeS’ potential as a novel treatment in enabling transplantation in sensitized patients.
More on IdeS
The enzyme IdeS is developed as a fast, safe and expedient method to deactivate anti-HLA antibodies in sensitized patients prior to kidney transplantation. For sensitized patients, anti-HLA antibodies pose the primary obstacle to become transplanted, and the patients are referred to long-term dialysis. A successful Phase I-study with IdeS was finalized in January 2014. A Phase II study application for treatment of sensitized kidney transplantation patients has been approved by the Swedish Medical Products Agency, and the study is scheduled for 2014.
For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO Hansa Medical AB (publ)
Mobile: 46 707 17 54 77